Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M, Rowland, Andrew, Kichenadasse, Ganessan, Wiese, Michael D, Gurney, Howard, McKinnon, Ross A, Karapetis, Chris S, Sorich, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625676/
https://www.ncbi.nlm.nih.gov/pubmed/28950287
http://dx.doi.org/10.1038/bjc.2017.274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625676/
https://www.ncbi.nlm.nih.gov/pubmed/28950287
http://dx.doi.org/10.1038/bjc.2017.274

Ejemplares similares